Home›Companies›Biotech & Pharma›Praeventix

Praeventix, Inc.

Develops potential treatments for people with chronic itching and other disorders.

No LinkedIn page we could confirm. Why?
Updated Nov 9, 2026·Latest SEC filing Sep 10, 2026·Suggest an edit

About Praeventix

Praeventix is a private company based in Exton, Pennsylvania, incorporated in 2022 in Delaware. It has reported $16,732,955 raised in three offerings on Form D since November 2022. Its chief executive is Heidi Kempinski.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Feb 3, 2026Feb 13, 2026amended Sep 10, 2026$5,601,950fully sold9$622KEquityRule 506(b)Form D/A ↗1 earlier filing
May 8, 2025May 20, 2025$6,810,559fully sold9$756KEquityRule 506(b)Form D ↗
Oct 26, 2022Nov 8, 2022amended May 16, 2024$4,320,446fully sold3$1.4MEquityRule 506(b)Form D/A ↗2 earlier filings
Total, three offerings$16,732,955

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Praeventix's Form D filed Sep 10, 2026.

DP
Douglas Pippin, PhD
Executive officer and director
LM
Leon Moulder
Executive Chair
RH
HK

Earlier filings also listed Leonard Moulder, Jr. (director, last listed May 2025).

Sources

  1. SECPraeventix, Inc. Form D, filed Feb 13, 2026
  2. SECPraeventix, Inc. Form D/A, filed Apr 21, 2023
  3. SECPraeventix, Inc. Form D, filed Nov 8, 2022
  4. SECPraeventix, Inc. filing history